3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Leukemia
13
Lymphoma
3
Leukemia, Myeloid, Acute
3
Recurrence
2
Neoplasms
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Leukemia, Biphenotypic, Acute
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Glioblastoma
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Surveys and Questionnaires
114
Exercise
103
Blood Specimen Collection
99
Radiotherapy
67
Gemcitabine
64
Bevacizumab
57
Standard of Care
56
Cisplatin
55
Cyclophosphamide
51
Capecitabine
50
Carboplatin
49
Docetaxel
47
pembrolizumab
46
Dexamethasone
46
Paclitaxel
45
Interviews as Topic
43
Oxaliplatin
40
Magnetic Resonance Spectroscopy
39
Fluorouracil
37
Methods
36
Irinotecan
36
Therapeutics
33
Drug Therapy
33
Radiosurgery
31
Nivolumab
30
Erlotinib Hydrochloride
27
Educational Status
26
Everolimus
24
Leucovorin
23
Control Groups
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms
×
Thioguanine
×
Clear all
NCT06351306
2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2
Withdrawn
NCT02912676
2020-04-15
TEAM
Rigshospitalet, Denmark
Phase 1/2
Completed
30 enrolled